厄达替尼在国内上市了吗？

Immunotherapy is currently a conventional method for treating bladder cancer, but it can only show excellent therapeutic effects on some patients. Compared with other malignant tumors, bladder cancer has been relatively lacking in targeted therapy. It has anti-tumor activity and can help treat patients with advanced bladder cancer and locally metastasized bladder cancer.

Erdafitinib is an FGFR1-4 tyrosine kinase inhibitor with anti-tumor activity. Mutations in the gene encoding fibroblast growth factor receptor (FGFR) are relatively common in urothelial cancer. Therefore, it can help patients with bladder cancer open up a new treatment path. The side effects of this targeted therapy are much smaller than traditional radiotherapy and chemotherapy. In addition to improving the patient's progression-free survival, it can also improve the patient's quality of life. 

In April 2019, erdafitinib was approved by the US FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who carry FGFR2/3 mutations or fusions and have disease progression during or after platinum-based chemotherapy (including within one year of neoadjuvant chemotherapy or adjuvant chemotherapy). Erdafitinib became the world's first targeted drug for urothelial cancer approved for marketing. (Urothelial cancer refers to tumors that occur in the kidneys, bladder, ureters, etc.)

Is erdafitinib available in China?

It is understood that it has not been listed in mainland China yet, but it has been listed in Hong Kong. For more information about erdafitinib, you can consult Medical Travel at any time!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: